1. Diana GD, Treasurywala AM, Bailey TR, Oglesby RC, Pevear DC, Dutko FJ.. (1990) A model for compounds active against human rhinovirus-14 based on X-ray crystallography data., 33 (5): [PMID:2158559] [10.1021/jm00167a006] |
2. Leclerc F, Cedergren R.. (1998) Modeling RNA-ligand interactions: the Rev-binding element RNA-aminoglycoside complex., 41 (2): [PMID:9457241] [10.1021/jm970372r] |
3. Diana GD, McKinlay MA, Otto MJ, Akullian V, Oglesby C.. (1985) [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles. Inhibitors of picornavirus uncoating., 28 (12): [PMID:2999407] [10.1021/jm00150a025] |
4. Diana GD, Oglesby RC, Akullian V, Carabateas PM, Cutcliffe D, Mallamo JP, Otto MJ, McKinlay MA, Maliski EG, Michalec SJ.. (1987) Structure-activity studies of 5-[[4-(4,5-dihydro-2-oxazolyl) phenoxy]alkyl]-3-methylisoxazoles: inhibitors of picornavirus uncoating., 30 (2): [PMID:3027340] [10.1021/jm00385a021] |
5. Diana GD, Otto MJ, Treasurywala AM, McKinlay MA, Oglesby RC, Maliski EG, Rossmann MG, Smith TJ.. (1988) Enantiomeric effects of homologues of disoxaril on the inhibitory activity against human rhinovirus-14., 31 (3): [PMID:2831362] [10.1021/jm00398a009] |
6. Massa S, Artico M, Mai A, Ragno R, Corelli F, Pani A, Marongiu M, Tramontano E, La Colla P. (1991) Synthesis of new disoxaril analogues with potent and selective anti-human rhinovirus 14 activity, 1 (11): [10.1016/S0960-894X(01)81153-7] |
7. Klebe G, Abraham U.. (1993) On the prediction of binding properties of drug molecules by comparative molecular field analysis., 36 (1): [PMID:8380615] [10.1021/jm00053a009] |
8. Massa S, Corelli F, Artico M, Mai A, Ragno R, De Montis A, Loi AG, Corrias S, Marongiu ME, La Colla P.. (1995) [[[(Thienylcarbonyl)alkyl]oxy]phenyl]- and [[[(pyrrylcarbonyl)alkyl]oxy]phenyl]oxazoline derivatives with potent and selective antihuman rhinovirus activity., 38 (5): [PMID:7877145] [10.1021/jm00005a007] |
9. Spasova M, Philipov S, Nikolaeva-Glomb L, Galabov AS, Milkova Ts.. (2008) Cinnamoyl- and hydroxycinnamoyl amides of glaucine and their antioxidative and antiviral activities., 16 (15): [PMID:18590964] [10.1016/j.bmc.2008.06.010] |
10. Martucci WE, Udier-Blagovic M, Atreya C, Babatunde O, Vargo MA, Jorgensen WL, Anderson KS.. (2009) Novel non-active site inhibitor of Cryptosporidium hominis TS-DHFR identified by a virtual screen., 19 (2): [PMID:19059777] [10.1016/j.bmcl.2008.11.054] |
11. USP Dictionary of USAN and International Names (2010 edition) and USAN registrations 2007-date, |
12. Han X, Sun N, Wu H, Guo D, Tien P, Dong C, Wu S, Zhou HB.. (2016) Identification and Structure-Activity Relationships of Diarylhydrazides as Novel Potent and Selective Human Enterovirus Inhibitors., 59 (5): [PMID:26885567] [10.1021/acs.jmedchem.5b01803] |
13. Egorova A, Ekins S, Schmidtke M, Makarov V.. (2019) Back to the future: Advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses., 178 [PMID:31226653] [10.1016/j.ejmech.2019.06.008] |
14. Ellen Van Damme. (2021) Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity, [10.6019/CHEMBL4651402] |